Swiss National Bank Has $2.12 Million Stake in Aerie Pharmaceuticals, Inc. (AERI)

Swiss National Bank boosted its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 8.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,800 shares of the company’s stock after buying an additional 3,600 shares during the period. Swiss National Bank owned 0.14% of Aerie Pharmaceuticals worth $2,122,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Guggenheim Capital LLC raised its stake in Aerie Pharmaceuticals by 4.2% in the fourth quarter. Guggenheim Capital LLC now owns 34,135 shares of the company’s stock valued at $1,292,000 after buying an additional 1,384 shares in the last quarter. First Mercantile Trust Co. raised its stake in Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock valued at $319,000 after buying an additional 1,620 shares in the last quarter. Federated Investors Inc. PA raised its stake in Aerie Pharmaceuticals by 88.7% in the fourth quarter. Federated Investors Inc. PA now owns 4,447 shares of the company’s stock valued at $168,000 after buying an additional 2,090 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its stake in Aerie Pharmaceuticals by 15.8% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,721 shares of the company’s stock valued at $784,000 after buying an additional 2,828 shares in the last quarter. Finally, Fox Run Management L.L.C. raised its stake in Aerie Pharmaceuticals by 49.3% in the first quarter. Fox Run Management L.L.C. now owns 9,558 shares of the company’s stock valued at $433,000 after buying an additional 3,158 shares in the last quarter. Institutional investors and hedge funds own 91.75% of the company’s stock.

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) opened at 54.00 on Thursday. The company’s market cap is $1.82 billion. Aerie Pharmaceuticals, Inc. has a 52 week low of $16.45 and a 52 week high of $59.50. The company’s 50-day moving average is $46.85 and its 200-day moving average is $44.12.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. On average, analysts anticipate that Aerie Pharmaceuticals, Inc. will post ($2.59) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2017/06/22/swiss-national-bank-has-2-12-million-stake-in-aerie-pharmaceuticals-inc-aeri.html.

Several equities analysts recently commented on the stock. Cantor Fitzgerald set a $56.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, April 12th. Canaccord Genuity set a $56.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, March 11th. HC Wainwright set a $69.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, April 15th. Aegis increased their price objective on shares of Aerie Pharmaceuticals from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $58.00 price objective (up previously from $52.00) on shares of Aerie Pharmaceuticals in a research note on Wednesday, March 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $61.00.

In related news, Director Gerald D. Cagle acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, April 19th. The stock was acquired at an average cost of $41.70 per share, for a total transaction of $83,400.00. Following the acquisition, the director now owns 10,900 shares of the company’s stock, valued at $454,530. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $55.95, for a total transaction of $1,119,000.00. The disclosure for this sale can be found here. 9.36% of the stock is currently owned by corporate insiders.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply